دورية أكاديمية
Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
| العنوان: | Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer |
|---|---|
| المؤلفون: | de Wit, Ronald, de Bono, Johann, Sternberg, Cora N., Fizazi, Karim, Tombal, Bertrand, Wülfing, Christian, Kramer, Gero, Eymard, Jean-Christophe, Bamias, Aristotelis, Carles, Joan, Iacovelli, Roberto, Melichar, Bohuslav, Sverrisdóttir, Ásgerður, Theodore, Christine, Feyerabend, Susan, Helissey, Carole, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, Castellano, Daniel, CARD Investigators, missing, Rottey, Sylvie |
| المصدر: | NEW ENGLAND JOURNAL OF MEDICINE ; ISSN: 0028-4793 ; ISSN: 1533-4406 |
| سنة النشر: | 2019 |
| المجموعة: | Ghent University Academic Bibliography |
| مصطلحات موضوعية: | Medicine and Health Sciences, General Medicine, DOCETAXEL TREATMENT, ANTITUMOR-ACTIVITY, INCREASED SURVIVAL, OPEN-LABEL, PHASE-III, PREDNISONE, THERAPY, MEN, CHEMOTHERAPY, MITOXANTRONE |
| الوصف: | A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling-targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response. Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear. Methods We randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed. Results A total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling-targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P=0.008). The median ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://biblio.ugent.be/publication/8730504Test; http://hdl.handle.net/1854/LU-8730504Test; http://dx.doi.org/10.1056/nejmoa1911206Test; https://biblio.ugent.be/publication/8730504/file/8730505Test |
| DOI: | 10.1056/nejmoa1911206 |
| الإتاحة: | https://doi.org/10.1056/nejmoa1911206Test https://biblio.ugent.be/publication/8730504Test http://hdl.handle.net/1854/LU-8730504Test https://biblio.ugent.be/publication/8730504/file/8730505Test |
| حقوق: | No license (in copyright) ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.388A52DD |
| قاعدة البيانات: | BASE |
| DOI: | 10.1056/nejmoa1911206 |
|---|